Enfortumab vedotin with or without pembrolizumab offers disease control benefits for patients with upper tract urothelial cancer, said Evangelia Vlachou, MD, of Johns Hopkins Medicine.
Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback